Current Lab Members

Vishal Khivansara, M.S., Sr. Research Scientist

Vishal Khivansara, M.S., Sr. Research Scientist

After graduation, Vishal trained at Rockefeller University and the University of Michigan, specializing in miRNAs and RNAi. He has been part of Dr. Nijhawan’s research group for the past four years, where he currently focuses on identifying small molecules that selectively target leukemias.

Shanhai Xie, Ph.D., Sr. Research Scientist

Shanhai Xie, Ph.D., Sr. Research Scientist

Dr. Xie received his graduate training in the laboratory of Dr. Ralph Arlinghaus at The University of Texas MD Anderson Cancer Center. Following this, he completed his postdoctoral training in the laboratory of Dr. Steve McKnight at UT Southwestern Medical Center. He then joined Peloton Therapeutics, where he worked from its inception until its acquisition by Merck. Afterward, Dr. Xi returned to UT Southwestern to join Dr. Deepak Nijhawan’s laboratory, focusing on small molecule drug discovery.

Min Fang, Ph.D.

Min Fang, Ph.D., Scientist

Dr. Fan is currently focused on selecting small molecule toxins that bind mutant proteins using inducible forward genetics.

Ashley Leach

Ashley Leach, B.S., Sr. Research Associate

Ashley Leach is a Research Associate with over 8 years of experience in the biomedical research field. Within the Nijhawan lab, Ashley assists with in vivo and ex vivo experiments focused on studying the pharmacokinetics and pharmacodynamics of the lab’s assorted small molecule library. The overarching goal of these studies is to identify and validate protein targets for small molecules with anti-cancer activity. Ashley received a Bachelor of Science in Kinesiology from the University of North Texas in 2013.
 

Placeholder image

Jacob Kimberg, Research Technician I

Rutuja

Rutuja Dighe, Research Associate

Rutuja completed her Master's in Pharmaceutical Sciences and Drug Delivery from Northeastern University in December 2021. During her studies, she focused on inhibiting intercellular communication mediated by tunneling nanotubes (including mitochondrial transfer within these tubes) in triple-negative breast cancer. Concurrently, she interned at AbbVie in Cambridge, working in the Translational Immunology Department on Ulcerative Colitis and EAE (Experimental Autoimmune Encephalomyelitis). Following her master's degree, Rutuja joined AbbVie in San Francisco as an Associate Scientist II in the Oncology Discovery Research Department. There, she contributed to small molecule research and target validation for lung and pancreatic cancer. Currently, she works as a Research Associate in Dr. Nijhawan's Lab in the Radiation Oncology Department. Her work primarily involves screening molecules for efficacy, guiding cloning processes, testing guide efficiency, and generating knock-ins.

Terry Mann

Terry Mann, Research Associate

Terry Mann is a Research Associate with seven years of research experience, including two years in the industry. She earned a Bachelor of Science in Biology from Sam Houston State University in 2017. In the Nijhawan lab, Terry focuses on evaluating the feasibility of targeting novel pathways with small molecules that have demonstrated anticancer properties. She collaborates with a team of biologists to assess these small molecules for potential clinical development.

Pano Theodoropoulos, M.D., Ph.D.,

Pano Theodoropoulos, M.D., Ph.D., Clinical Fellow

Dr. Theodoropoulos is a physician-scientist fellow in medical oncology, currently training under the Physician Scientist Training Program (PSTP). His passion lies in bridging laboratory discoveries with patient care. He earned dual degrees (B.S./B.A.) in Biochemistry and Chemistry from the University of Chicago before completing his M.D./Ph.D. at UT Southwestern, where he trained under the mentorship of Dr. Deepak Nijhawan. Dr. Theodoropoulos had the privilege of working in the labs of Drs. Jonathan Graff, Steve McKnight, Deepak Nijhawan, and Bruce Beutler. These experiences fueled his fascination with the interactions between bioactive chemicals and biological systems, and he i particularly interested in identifying novel therapeutic targets for cancer treatment.

Kurt Reichermeir, M.D., Ph.D.

Kurt Reichermeir, M.D., Ph.D., Clinical Fellow

Kurt Michael Reichermeier grew up in Germany and earned his medical degrees, M.D. (2014) and Dr. med. (2015), from Medizinische Hochschule Hannover and Justus-Liebig Universität Giessen. In 2015, he moved to the United States to train with Raymond J. Deshaies at the California Institute of Technology (Caltech), and with Ingrid Wertz and Donald S. Kirkpatrick at Genentech, Inc. During this time, he pursued graduate studies in biology and earned a Ph.D. from Caltech.

In 2020, Dr. Reichermeier joined the Physician Scientist Training Program at UT Southwestern, where he completed residency training in Internal Medicine in 2022 and Clinical Fellowship Training in Pulmonary & Critical Care Medicine in 2024. He is currently a postdoctoral research fellow in the Nijhawan Laboratory, where his research focuses on the molecular mechanisms of tissue fibrosis and the development of antifibrotic therapies.

Current Students

Holly

Holly Guo, MSTP student

Holly received a B.S. in Biomedical Engineering from Johns Hopkins University, where she trained under Dr. Charles Eberhart and Eric Raabe. She matriculated into the UTSW Medical Scientist Training Program in 2020 and completed two years of medical school before joining the Nijhawan Lab. Holly is passionate about cancer drug discovery. She is currently studying mechanisms of small molecules that are cytotoxic to cancer cells.

Harrison Brown

Harrison Brown, Graduate student

Harrison Brown is a student in the Graduate School of Biomedical Sciences studying biological chemistry in the Nijhawan Lab. Previously, he studied human papillomavirus (HPV) oncogenes as an undergraduate at the University of Oklahoma, and cancer metabolism as a research assistant at UT Southwestern. His current projects utilize chemical biology and genetics to identify the functional target of novel anticancer chemical scaffolds.